

Study Title	Published date	Study drug	Study design	Safety data	Efficacy data	Study status
Safety and efficacy of apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecology malignant neoplasm. Guntupalli et al	2020	Apixaban 2.5mg twice daily oral vs enoxaparin 40mg subcutaneous daily	RCT N=500	Major bleeding: 1 event in each group (OR 1.04 CI 0.07-16.76). Non major bleeding 5.4% vs 9.7%	no difference in VTE events in both groups, 1% in apixaban arm and 1.5% in LMWH arm (OR 0.63 CI 0.12-3.75)	Complete
Postoperative thromboprophylaxis with oral rivaroxaban versus subcutaneous low-molecular-weight heparin: a retrospective comparison in women with a gynecologic malignancy Swaroop et al	2021	Rivaroxaban 10mg daily vs enoxaparin 40mg subcutaneous daily	Retrospective N= 315	Major bleeding events were 0.4% (1/233) in patients receiving enoxaparin compared to 3.7% (3/82) in those receiving rivaroxaban (p=0.06)	Incidence of VTE at 30 days in the enoxaparin group was 1.7% (4/233) compared to 1.2% (1/82) in the rivaroxaban group (p=1.00).	Complete
Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs Enoxaparin (VALERIA) Ramacciotti E	Not published	Rivaroxaban 10mg daily vs enoxaparin 40mg subcutaneous daily	RCT Estimated enrollement = 440	Pending	Pending	Ongoing

